Please use this identifier to cite or link to this item:
https://doi.org/10.3390/cancers13205147
DC Field | Value | |
---|---|---|
dc.title | Janus Kinase Signaling: Oncogenic Criminal of Lymphoid Cancers | |
dc.contributor.author | Li, Boheng | |
dc.contributor.author | Wan, Qin | |
dc.contributor.author | Li, Zhubo | |
dc.contributor.author | Chng, Wee-Joo | |
dc.date.accessioned | 2022-07-21T05:11:49Z | |
dc.date.available | 2022-07-21T05:11:49Z | |
dc.date.issued | 2021-10-01 | |
dc.identifier.citation | Li, Boheng, Wan, Qin, Li, Zhubo, Chng, Wee-Joo (2021-10-01). Janus Kinase Signaling: Oncogenic Criminal of Lymphoid Cancers. CANCERS 13 (20). ScholarBank@NUS Repository. https://doi.org/10.3390/cancers13205147 | |
dc.identifier.issn | 20726694 | |
dc.identifier.uri | https://scholarbank.nus.edu.sg/handle/10635/228997 | |
dc.description.abstract | The Janus kinase (JAK) family are known to respond to extracellular cytokine stimuli and to phosphorylate and activate signal transducers and activators of transcription (STAT), thereby modulating gene expression profiles. Recent studies have highlighted JAK abnormality in inducing over-activation of the JAK/STAT pathway, and that the cytoplasmic JAK tyrosine kinases may also have a nuclear role. A couple of anti-JAK therapeutics have been developed, which effectively harness lymphoid cancer cells. Here we discuss mutations and fusions leading to JAK deregulations, how up-stream nodes drive JAK expression, how classical JAK/STAT pathways are represented in lymphoid malignancies and the noncanonical and nuclear role of JAKs. We also summarize JAK inhibition therapeutics applied alone or synergized with other drugs in treating lymphoid malignancies. | |
dc.language.iso | en | |
dc.publisher | MDPI | |
dc.source | Elements | |
dc.subject | Science & Technology | |
dc.subject | Life Sciences & Biomedicine | |
dc.subject | Oncology | |
dc.subject | <p>JAK/STAT</p> | |
dc.subject | lymphoma | |
dc.subject | myeloma | |
dc.subject | inhibitor | |
dc.subject | B-CELL LYMPHOMA | |
dc.subject | CLASSICAL HODGKIN LYMPHOMA | |
dc.subject | JAK-STAT PATHWAY | |
dc.subject | MULTIPLE-MYELOMA CELLS | |
dc.subject | IN-VITRO | |
dc.subject | KAPPA-B | |
dc.subject | ANTITUMOR-ACTIVITY | |
dc.subject | JAK/STAT PATHWAY | |
dc.subject | GENE-REGULATION | |
dc.subject | PHASE-I | |
dc.type | Review | |
dc.date.updated | 2022-07-17T12:06:07Z | |
dc.contributor.department | DEAN'S OFFICE (MEDICINE) | |
dc.description.doi | 10.3390/cancers13205147 | |
dc.description.sourcetitle | CANCERS | |
dc.description.volume | 13 | |
dc.description.issue | 20 | |
dc.published.state | Published | |
Appears in Collections: | Staff Publications Elements |
Show simple item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
Janus Kinase Signaling Oncogenic Criminal of Lymphoid Cancers.pdf | Published version | 5.67 MB | Adobe PDF | OPEN | Published | View/Download |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.